These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

614 related items for PubMed ID: 28319070

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Reprogramming of the FOXA1 cistrome in treatment-emergent neuroendocrine prostate cancer.
    Baca SC, Takeda DY, Seo JH, Hwang J, Ku SY, Arafeh R, Arnoff T, Agarwal S, Bell C, O'Connor E, Qiu X, Alaiwi SA, Corona RI, Fonseca MAS, Giambartolomei C, Cejas P, Lim K, He M, Sheahan A, Nassar A, Berchuck JE, Brown L, Nguyen HM, Coleman IM, Kaipainen A, De Sarkar N, Nelson PS, Morrissey C, Korthauer K, Pomerantz MM, Ellis L, Pasaniuc B, Lawrenson K, Kelly K, Zoubeidi A, Hahn WC, Beltran H, Long HW, Brown M, Corey E, Freedman ML.
    Nat Commun; 2021 Mar 30; 12(1):1979. PubMed ID: 33785741
    [Abstract] [Full Text] [Related]

  • 3. Expression and role of Foxa proteins in prostate cancer.
    Mirosevich J, Gao N, Gupta A, Shappell SB, Jove R, Matusik RJ.
    Prostate; 2006 Jul 01; 66(10):1013-28. PubMed ID: 16001449
    [Abstract] [Full Text] [Related]

  • 4. Identification of Novel Diagnosis Biomarkers for Therapy-Related Neuroendocrine Prostate Cancer.
    Zhang C, Qian J, Wu Y, Zhu Z, Yu W, Gong Y, Li X, He Z, Zhou L.
    Pathol Oncol Res; 2021 Jul 01; 27():1609968. PubMed ID: 34646089
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. SRRM4 Drives Neuroendocrine Transdifferentiation of Prostate Adenocarcinoma Under Androgen Receptor Pathway Inhibition.
    Li Y, Donmez N, Sahinalp C, Xie N, Wang Y, Xue H, Mo F, Beltran H, Gleave M, Wang Y, Collins C, Dong X.
    Eur Urol; 2017 Jan 01; 71(1):68-78. PubMed ID: 27180064
    [Abstract] [Full Text] [Related]

  • 8. RNA Splicing of the BHC80 Gene Contributes to Neuroendocrine Prostate Cancer Progression.
    Li Y, Xie N, Chen R, Lee AR, Lovnicki J, Morrison EA, Fazli L, Zhang Q, Musselman CA, Wang Y, Huang J, Gleave ME, Collins C, Dong X.
    Eur Urol; 2019 Aug 01; 76(2):157-166. PubMed ID: 30910347
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Alternative RNA splicing of the MEAF6 gene facilitates neuroendocrine prostate cancer progression.
    Lee AR, Li Y, Xie N, Gleave ME, Cox ME, Collins CC, Dong X.
    Oncotarget; 2017 Apr 25; 8(17):27966-27975. PubMed ID: 28427194
    [Abstract] [Full Text] [Related]

  • 11. SRC family kinase FYN promotes the neuroendocrine phenotype and visceral metastasis in advanced prostate cancer.
    Gururajan M, Cavassani KA, Sievert M, Duan P, Lichterman J, Huang JM, Smith B, You S, Nandana S, Chu GC, Mink S, Josson S, Liu C, Morello M, Jones LW, Kim J, Freeman MR, Bhowmick N, Zhau HE, Chung LW, Posadas EM.
    Oncotarget; 2015 Dec 29; 6(42):44072-83. PubMed ID: 26624980
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. BRN4 Is a Novel Driver of Neuroendocrine Differentiation in Castration-Resistant Prostate Cancer and Is Selectively Released in Extracellular Vesicles with BRN2.
    Bhagirath D, Yang TL, Tabatabai ZL, Majid S, Dahiya R, Tanaka Y, Saini S.
    Clin Cancer Res; 2019 Nov 01; 25(21):6532-6545. PubMed ID: 31371344
    [Abstract] [Full Text] [Related]

  • 14. Alternative splicing of LSD1+8a in neuroendocrine prostate cancer is mediated by SRRM4.
    Coleman DJ, Sampson DA, Sehrawat A, Kumaraswamy A, Sun D, Wang Y, Schwartzman J, Urrutia J, Lee AR, Coleman IM, Nelson PS, Dong X, Morrissey C, Corey E, Xia Z, Yates JA, Alumkal JJ.
    Neoplasia; 2020 Jun 01; 22(6):253-262. PubMed ID: 32403054
    [Abstract] [Full Text] [Related]

  • 15. Proteogenomic Characterization of Patient-Derived Xenografts Highlights the Role of REST in Neuroendocrine Differentiation of Castration-Resistant Prostate Cancer.
    Flores-Morales A, Bergmann TB, Lavallee C, Batth TS, Lin D, Lerdrup M, Friis S, Bartels A, Kristensen G, Krzyzanowska A, Xue H, Fazli L, Hansen KH, Røder MA, Brasso K, Moreira JM, Bjartell A, Wang Y, Olsen JV, Collins CC, Iglesias-Gato D.
    Clin Cancer Res; 2019 Jan 15; 25(2):595-608. PubMed ID: 30274982
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. ONECUT2 is a driver of neuroendocrine prostate cancer.
    Guo H, Ci X, Ahmed M, Hua JT, Soares F, Lin D, Puca L, Vosoughi A, Xue H, Li E, Su P, Chen S, Nguyen T, Liang Y, Zhang Y, Xu X, Xu J, Sheahan AV, Ba-Alawi W, Zhang S, Mahamud O, Vellanki RN, Gleave M, Bristow RG, Haibe-Kains B, Poirier JT, Rudin CM, Tsao MS, Wouters BG, Fazli L, Feng FY, Ellis L, van der Kwast T, Berlin A, Koritzinsky M, Boutros PC, Zoubeidi A, Beltran H, Wang Y, He HH.
    Nat Commun; 2019 Jan 17; 10(1):278. PubMed ID: 30655535
    [Abstract] [Full Text] [Related]

  • 18. GRK3 is a direct target of CREB activation and regulates neuroendocrine differentiation of prostate cancer cells.
    Sang M, Hulsurkar M, Zhang X, Song H, Zheng D, Zhang Y, Li M, Xu J, Zhang S, Ittmann M, Li W.
    Oncotarget; 2016 Jul 19; 7(29):45171-45185. PubMed ID: 27191986
    [Abstract] [Full Text] [Related]

  • 19. Androgen deprivation-induced ZBTB46-PTGS1 signaling promotes neuroendocrine differentiation of prostate cancer.
    Chen WY, Zeng T, Wen YC, Yeh HL, Jiang KC, Chen WH, Zhang Q, Huang J, Liu YN.
    Cancer Lett; 2019 Jan 19; 440-441():35-46. PubMed ID: 30312731
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.